The Journal of the Korean bone and joint tumor society (대한골관절종양학회지)

The Korean Musculoskeletal Tumor Society (대한근골격종양학회)
권호 표지
DOI QR코드

DOI QR Code

An Atypical Subtrochanteric Femoral Fracture in a Patient with Multiple Myeloma Received Zoledronic Acid: A Case Report

졸레드론산을 투여한 다발성 골수종 환자에서 발생한 비전형적 대퇴골 전자하 골절: 증례 보고

  • Jeong, Won-Ju (Department of Orthopedic Surgery, Kyungpook National University Hospital) ;
  • Na, Sang-Bong (Department of Orthopedic Surgery, Kyungpook National University Hospital) ;
  • Cho, Hwan-Seong (Department of Orthopedic Surgery, Seoul National University Bundang Hospital) ;
  • Kim, Joon-Woo (Department of Orthopedic Surgery, Kyungpook National University Hospital) ;
  • Park, Il-Hyung (Department of Orthopedic Surgery, Kyungpook National University Hospital)
  • 정원주 (경북대학교 의학전문대학원 정형외과학교실, 경북대학교병원 정형외과) ;
  • 나상봉 (경북대학교 의학전문대학원 정형외과학교실, 경북대학교병원 정형외과) ;
  • 조환성 (서울대학교 의학전문대학원 정형외과학교실, 분당서울대학교병원 정형외과) ;
  • 김준우 (경북대학교 의학전문대학원 정형외과학교실, 경북대학교병원 정형외과) ;
  • 박일형 (경북대학교 의학전문대학원 정형외과학교실, 경북대학교병원 정형외과)
  • Received : 2012.10.04
  • Accepted : 2012.11.22
  • Published : 2012.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Little literature exists about the risk of atypical femoral fracture in patients received zoledronic acid for prevention of skeletal metastasis. We report an atypical subtrochanteric femoral fracture in a patient with multiple myeloma received zoledronic acid. The patient was treated by closed reduction and internal fixation with cephalomedullary nailing.

악성 종양 환자에게서 졸레드론산과 같은 비스포스포네이트를 예방적으로 투여받은 경우 이와 관련한 비전형적 대퇴골 골절의 발생 위험성은 아직까지 명확하게 밝혀진 바가 없으며, 국내에 지금까지 보고된 예가 매우 드물다. 본 증례는 다발성 골수종 환자에서 고농도 졸레드론산을 지속적으로 투여받았던 환자에서 큰 외상의 병력 없이 우측 대퇴골 전자하 부위의 비전형적 골절이 발생한 경우로 폐쇄적 정복술 및 골수강 내 금속정 내고정술로 치료한 경험을 보고하고자 한다.

Keywords

References

  1. Wardley A, Davidson N, Barrett-Lee P, et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer. 2005;92:1869-76.
  2. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294-301.
  3. Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol. 1998;16:3890-9.
  4. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613-21.
  5. Pazianas M, Cooper C, Ebetino FH, Russell RG. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag. 2010;6:325-43.
  6. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39:224-31.
  7. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15:613-20.
  8. Kyle RA, Yee GC, Somerfield MR, et al; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25:2464-72.
  9. Van Poznak CH, Temin S, Yee GC, et al; American Society of Clinical Oncology. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011;29:1221-7.
  10. Puhaindran ME, Farooki A, Steensma MR, Hameed M, Healey JH, Boland PJ. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. J Bone Joint Surg Am. 2011;93:1235-42.